CYAD.BR StockTwits Mentions

Track CYAD.BR's AI-powered predictions, market trends, and investment insights.

CYAD.BR AI Prediction CYAD.BR Sentiment CYAD.BR Reddit

Mock Tradesimulated, no real money

You don't hold CYAD.BR in your mock portfolio yet.

CYAD.BR StockTwits Mentions

Track CYAD.BR's AI-powered predictions, market trends, and investment insights.

CYAD.BR AI Prediction CYAD.BR Sentiment CYAD.BR Reddit

Evidence Stack

What Changed?

Key moves vs recent baseline (last day / last week)

Price (1d)-7.1%

Price (7d)-12.4%

Volume vs avg0.6x

Volatility vs normal1.3x

Why Now?

Plain-English summary of the biggest drivers (informational)

Risk Flags

Potential risk factors to review

Low liquidity

Avg volume 14K — may be hard to exit

Based on earnings timing, volatility, liquidity and crowd activity. Informational signals only — not investment advice.

Invalidation Signals

Reassess your thesis if any of these occur:

Price breaks below ~€0.26 (recent support level)

Upgrade to see the full Evidence Stack

What Changed, Why Now, and Risk Flags — available on the Investor plan and above

Get Started

CYAD.BR AI Stock Analysis

Financial Performance

neutral

The company is marginally profitable on an EPS basis, with a PE ratio of 14.95 and EPS of 0.02, which is unusual for an early‑stage oncology name but likely reflects very small absolute earnings and a tiny equity value. Without detailed revenue and margin data, the sustainability of profitability is unclear, and the valuation multiple is only moderately demanding on headline numbers. Overall, the financial picture appears fragile but not outright distressed based on the limited metrics provided.

Positive EPS of 0.02 suggests the company is currently profitable on a per‑share basis, at least over the most recent reporting period.
A PE ratio of 14.95 is not excessive in isolation, but for a micro‑cap biotech it may reflect low earnings quality, one‑off items, or limited growth visibility rather than durable profitability.
Lack of visibility into revenue trends, gross profit, and margins implies that the current profitability may not be structurally secure, keeping the financial outlook only neutral rather than clearly positive.

Stock Price & Technicals

neutral

At €0.30, the stock trades modestly above its 200‑day moving average of €0.26, indicating a slight positive trend over the longer term, but the 1.0% decline over the last month points to recent weakness or consolidation. The proximity to the 200‑day average suggests the stock is neither in a strong uptrend nor a clear downtrend. Without an explicit RSI value, there is no strong technical signal of overbought or oversold conditions, so the technical picture appears balanced but fragile.

Current price (€0.30) is modestly above the 200‑day moving average (€0.26), which is mildly constructive but not indicative of a strong momentum phase.
The stock is down 1.0% over the last month, suggesting short‑term softness or a pause after prior gains rather than a decisive breakdown.
Absence of a stated RSI and the micro‑cap nature of the stock imply that liquidity and volatility risks are high, and technical signals should be treated with caution.

Alternative Data Signals

bearish

Alternative data suggest limited commercial traction and low external engagement: estimated web traffic is only 331 visitors per month, and social media growth appears stagnant, especially on YouTube. The company has zero job openings, which may indicate a lack of active expansion or new initiatives, consistent with a defensive or cash‑preservation stance. While LinkedIn and Twitter/X follower counts are non‑trivial for a small biotech, the overall signal from alternative data is weak and not supportive of a strong growth narrative.

Very low estimated website traffic (331 visitors/month) points to minimal digital engagement and limited inbound interest from patients, partners, or investors.
Zero job openings with 0.0% month‑over‑month change suggests no current hiring momentum, often a sign of constrained growth plans or a focus on conserving cash rather than scaling operations.
Social media presence is modest (2,243 Twitter/X followers, 496 YouTube subscribers with 0% growth over 90 days, 16,614 LinkedIn followers), and the lack of recent follower growth on key channels indicates stagnant external interest.

Conclusion

bearish

Overall, the combination of fragile profitability, a technically neutral price pattern, and weak alternative data signals skews the outlook toward bearish. While the stock trades slightly above its 200‑day moving average and shows positive EPS, these positives are outweighed by very low engagement, no hiring momentum, and the inherent risks of a small oncology company. Unless there is a clear upcoming catalyst or evidence of strengthening fundamentals, the risk‑reward profile appears unfavorable.

Neutral financial and technical profiles are overshadowed by weak alternative data, suggesting limited growth momentum or external validation.
Given the micro‑cap context, low engagement, and absence of expansion signals, the stock’s risk profile leans high with insufficient offsetting signs of accelerating demand or execution, supporting an overall bearish stance.

AI Score

Sell

Alternative2

Fundamental1

Technical5

Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.

Mock Tradesimulated, no real money

You don't hold CYAD.BR in your mock portfolio yet.